These advantages translate into elevated levels of IFN‐γ‐producing CD8+ T cells and TCF1+CD8+ T cells in tumors, leading to suppression of tumor growth compared to the standard neoantigen‐adjuvant mixture and commercial vaccine formulation such as SM102 and MC3 in the Hepa1‐6 cell‐based orthotopic HCC models and MC38 cell‐based colorectal cancer models by prolonging survival in mice. Here, CD8A is linked to neoplasm.